Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Phase 1/2 Completed 30 enrolled Mesoblast, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.

Timeline

Start: 2013-07
Primary completion: 2014-09
Completion: 2015-09

Publications

Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine. 2016 Oct;12:263-269. doi: 10.1016/j.ebiom.2016.09.011. Epub 2016 Sep 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rexlemestrocel-L	Cell therapy	1.5e+08 cells	Intravenous
Subject	Rexlemestrocel-L	Cell therapy	3e+08 cells	Intravenous

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Summary

Timeline

Publications

Drugs

Indications